EHC · Encompass Health Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.94B | $5.37B | $4.80B | $4.35B | $5.12B | $4.64B |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $236.20M | $209.20M | $201.70M | $154.30M | $197.30M | $155.50M |
| Total Operating Expenses | $4.88B | $4.51B | $4.07B | $3.72B | $4.32B | $4.00B |
| D&A | $327.90M | $299.60M | $273.90M | $243.60M | $256.60M | $243.00M |
| Operating Income | $953.00M | $749.60M | $607.20M | $539.50M | $657.20M | $563.90M |
| Interest Expense | $123.20M | $137.40M | $143.50M | $175.70M | $164.60M | $184.20M |
| Income Tax | $192.90M | $150.20M | $132.20M | $100.10M | $139.60M | $103.80M |
| Net Income | $566.20M | $455.70M | $352.00M | $271.00M | $412.20M | $284.20M |
| EPS - Basic | $5.62 | $4.53 | $3.51 | $2.72 | $3.30 | $2.28 |
| EPS - Diluted | $5.54 | $4.46 | $3.47 | $2.70 | $3.27 | $2.27 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $72.20M | $85.40M | $69.10M | $21.80M | $54.80M | $224.00M |
| Accounts Receivable | $613.40M | $593.00M | $599.80M | $524.80M | $666.60M | $563.00M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $178.20M | $171.00M | $170.00M | $132.90M | $137.60M | $115.00M |
| Current Assets | $905.90M | $886.90M | $841.80M | $717.20M | $921.40M | $948.60M |
| Total Assets | $7.09B | $6.53B | $6.10B | $5.64B | $6.86B | $6.45B |
| Current Liabilities | $836.40M | $841.00M | $656.40M | $575.90M | $748.80M | $717.30M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $3.81B | $3.69B | $3.81B | $3.77B | $4.47B | $4.44B |
| Stockholders' Equity | $2.44B | $2.07B | $1.65B | $1.31B | $1.91B | $1.59B |
| Retained Earnings | $1.29B | $796.70M | $406.50M | $115.70M | $141.80M | ($242.30M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.18B | $1.00B | $705.80M | $705.80M | $715.80M | $704.70M |
| Investing Cash Flow | ($764.60M) | ($653.30M) | ($602.80M) | ($627.00M) | ($666.30M) | ($407.50M) |
| Financing Cash Flow | ($431.20M) | ($330.60M) | ($197.20M) | ($145.70M) | ($240.10M) | ($145.90M) |
| CapEx | $736.40M | $642.50M | $583.10M | $564.80M | $528.90M | $396.00M |
| Free Cash Flow | $439.20M | $360.30M | $122.70M | $141.00M | $186.90M | $308.70M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 16.1% | 14.0% | 12.6% | 12.4% | 12.8% | 12.1% |
| EBITDA margin | 21.6% | 19.5% | 18.4% | 18.0% | 17.8% | 17.4% |
| Net margin | 9.5% | 8.5% | 7.3% | 6.2% | 8.0% | 6.1% |
| Free cash flow margin | 7.4% | 6.7% | 2.6% | 3.2% | 3.6% | 6.6% |
| FCF / Net income | 0.78 | 0.79 | 0.35 | 0.52 | 0.45 | 1.09 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 4.0% | 3.9% | 4.2% | 3.5% | 3.9% | 3.3% |
| Effective tax rate | 25.4% | 24.8% | 27.3% | 27.0% | 25.3% | 26.8% |
| Return on assets | 8.0% | 7.0% | 5.8% | 4.8% | 6.0% | 4.4% |
| Return on equity | 23.2% | 22.0% | 21.4% | 20.7% | 21.6% | 17.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.08 | 1.05 | 1.28 | 1.25 | 1.23 | 1.32 |
| Quick ratio | 1.08 | 1.05 | 1.28 | 1.25 | 1.23 | 1.32 |
| Cash ratio | 0.09 | 0.10 | 0.11 | 0.04 | 0.07 | 0.31 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 7.7x | 5.5x | 4.2x | 3.1x | 4.0x | 3.1x |
| Equity multiplier | 2.91 | 3.16 | 3.70 | 4.30 | 3.59 | 4.06 |
| Liabilities / Assets | 0.54 | 0.56 | 0.62 | 0.67 | 0.65 | 0.69 |
| Efficiency | ||||||
| Asset turnover | 0.84 | 0.82 | 0.79 | 0.77 | 0.75 | 0.72 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 38d | 40d | 46d | 44d | 48d | 44d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 19.2x | 20.7x | 19.2x | 22.2x | 15.9x | 29.0x |
| P / B | 4.4x | 4.6x | 4.1x | 4.6x | 2.7x | 4.1x |
| P / S | 1.8x | 1.8x | 1.4x | 1.4x | 1.0x | 1.4x |
| EV / EBITDA | 8.4x | 8.9x | 7.6x | 7.6x | 5.6x | 7.9x |
| Growth | ||||||
| Revenue growth (YoY) | 10.5% | 11.9% | 10.4% | -15.1% | 10.3% | 0.9% |
| Revenue CAGR (3y) | 10.9% | 1.6% | 1.1% | -1.9% | 12.0% | - |
| Revenue CAGR (5y) | 5.0% | 3.1% | 5.7% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 27.1% | 23.5% | 12.5% | -17.9% | 16.5% | -7.9% |
| Net income growth (YoY) | 24.2% | 29.5% | 29.9% | -34.3% | 45.0% | -20.8% |
| EPS growth (YoY) | 24.2% | 28.5% | 28.5% | -17.4% | 44.2% | -37.2% |
| EPS CAGR (3y) | 27.1% | 10.9% | 15.2% | -9.2% | 3.7% | -5.5% |
| EPS CAGR (5y) | 19.6% | 4.3% | 3.4% | 0.1% | 4.8% | 3.5% |
| FCF growth (YoY) | 21.9% | 193.6% | -13.0% | -24.6% | -39.5% | 17.4% |
| FCF CAGR (5y) | 7.3% | 6.5% | -24.7% | -20.0% | -15.3% | -2.8% |
| Book value growth (YoY) | 18.0% | 25.5% | 25.7% | -31.4% | 20.4% | 17.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$5.94B totalInpatient Rehabilitation$5.94B · 100.0%
Product / service
$5.94B totalInpatient$5.76B · 97.0%
Other$178.90M · 3.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.68
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
7/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Hospitals
Comparing Encompass Health Corp against the 3 most active filers in the same SIC group.
Dividends
$0.74/share trailing 12 months · +12.1% YoY
| Ex-date | Per share |
|---|---|
| Apr 1, 2026 | $0.1900 |
| Jan 2, 2026 | $0.1900 |
| Oct 1, 2025 | $0.1900 |
| Jul 1, 2025 | $0.1700 |
| Apr 1, 2025 | $0.1700 |
| Jan 2, 2025 | $0.1700 |
| Oct 1, 2024 | $0.1700 |
| Jul 1, 2024 | $0.1500 |
| Mar 28, 2024 | $0.1500 |
| Dec 29, 2023 | $0.1500 |
| Sep 29, 2023 | $0.1500 |
| Jun 30, 2023 | $0.1500 |
| Mar 31, 2023 | $0.1500 |
| Dec 30, 2022 | $0.1500 |
| Sep 30, 2022 | $0.1500 |
| Jul 12, 2022 | $0.2800 |
| Mar 31, 2022 | $0.2228 |
| Dec 31, 2021 | $0.2228 |
| Sep 30, 2021 | $0.2228 |
| Jun 30, 2021 | $0.2228 |
| Mar 31, 2021 | $0.2228 |
| Dec 31, 2020 | $0.2228 |
| Sep 30, 2020 | $0.2228 |
| Jun 30, 2020 | $0.2228 |